Factor Xa Inhibitors Tied to Interstitial Lung Disease in AF Factor Xa Inhibitors Tied to Interstitial Lung Disease in AF
Use of factor Xa inhibitors was associated with a higher risk of interstitial lung disease in Taiwanese patients with nonvalvular atrial fibrillation.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 23, 2022 Category: Neurology Tags: Cardiology News Source Type: news

Combo Therapy Shows Mixed Results for SSc-Related Lung Disease Combo Therapy Shows Mixed Results for SSc-Related Lung Disease
A study of mycophenolate mofetil alone and in combination with pirfenidone for scleroderma-related interstitial lung disease showed mixed results.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 17, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news

Safer Alternative to Cyclophosphamide at Hand for ILD?
(MedPage Today) -- PHILADELPHIA -- Rituximab (Rituxan) matched IV cyclophosphamide for improving lung function in patients with interstitial lung disease (ILD) related to systemic sclerosis and other connective tissue diseases, and was associated... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - November 14, 2022 Category: Rheumatology Source Type: news

CTD-ILD: Rituximab'a Reasonable Alternative to Cyclophosphamide'CTD-ILD: Rituximab'a Reasonable Alternative to Cyclophosphamide '
A clinical trial found that rituximab and cyclophosphamide had similar outcomes for interstitial lung disease associated with connective tissue disorders.MDedge News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 14, 2022 Category: Internal Medicine Tags: Rheumatology News Source Type: news

AI model predicts survival in idiopathic pulmonary fibrosis patients
A deep-learning model trained to measure total lung capacity on x-rays coul...Read more on AuntMinnie.comRelated Reading: CT plus histopathology boosts the accuracy of ILD diagnosis ECR: How will AI be utilized in chest imaging applications? Training helps novice CT readers identify interstitial lung disease Specialized CT training helps readers diagnose lung disease Animal study suggests Ga-68 PET FAPI can detect lung fibrosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 27, 2022 Category: Radiology Source Type: news

Pirfenidone Promising for RA-Linked Interstitial Lung Disease
TUESDAY, Oct. 4, 2022 -- Pirfenidone may slow the rate of decline of forced vital capacity (FVC) among patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD), according to a study published online Sept. 5 in The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2022 Category: Pharmaceuticals Source Type: news

Pirfenidone Shows Hints of Benefit for RA-Related Lung Disease
(MedPage Today) -- BARCELONA -- Rheumatoid arthritis patients with existing interstitial lung disease (ILD) had less decline in lung function when receiving the antifibrotic agent pirfenidone (Esbriet) relative to placebo in a randomized trial... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - September 6, 2022 Category: Rheumatology Source Type: news

CT plus histopathology boosts the accuracy of ILD diagnosis
The combination of high-resolution CT and histopathological data boosts radiologists...Read more on AuntMinnie.comRelated Reading: Dark-field chest x-ray differentiates lung disease Training helps novice CT readers identify interstitial lung disease Image search engine boosts chest CT diagnostic accuracy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 29, 2022 Category: Radiology Source Type: news

Risk for ILD/Pneumonitis Examined for Trastuzumab Deruxtecan
MONDAY, Aug. 22, 2022 -- For patients receiving trastuzumab deruxtecan (T-DXd) monotherapy, the incidence of adjudicated drug-related interstitial lung disease (ILD)/pneumonitis is 15.4 percent, according to a study published online Aug. 11 in ESMO... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 22, 2022 Category: Pharmaceuticals Source Type: news

Lung Adverse Effects in Patients Taking Trastuzumab Deruxtecan Lung Adverse Effects in Patients Taking Trastuzumab Deruxtecan
Cancer patients treated with the targeted agent need to be closely monitored for interstitial lung disease/pneumonitis as an adverse event, say researchers reporting a new analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 18, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Are Causes of Childhood Interstital Lung Disease?
Discussion Interstitial lung disease in children (chILD) is less understood than adult interstitial lung disease (ILD) and is rare. Prevalence is ~ 0.13 to 16.2 per 100,000 children under age 17 years. chILD is an general term for respiratory disorders that are heterogeneous, chronic and impair lung function. While some define diffuse parenchymal lung disease (DPLD) separately, the term ILD usually encompases DPLD. chILD has variable definitions and is “usually diagnosed if three of the following features are present: 1) respiratory symptoms (cough, rapid and/or difficult breathing, and exercise intolerance), 2) res...
Source: PediatricEducation.org - August 1, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT ® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations
July 26, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1b/2 CHRYSALIS-2 study (NCT04077463) cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw) with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) lazertinib and platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations.[1] These findings and additional updates, including data on RYBREVANT® in combination with laze...
Source: Johnson and Johnson - July 26, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Durable Efficacy for Drug Preventing Lung Progression in Systemic Sclerosis
(MedPage Today) -- Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said. Among participants who... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - July 20, 2022 Category: Rheumatology Source Type: news

Acute Exacerbations Common and Often Fatal in RA-ILD Acute Exacerbations Common and Often Fatal in RA-ILD
Acute exacerbations are common in RA-associated interstitial lung disease and a frequent cause of mortality.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - July 6, 2022 Category: Rheumatology Tags: Pulmonary Medicine News Source Type: news

Erica Herzog appointed John Slade Ely Professor of Medicine
Herzog directs Yale ’s Interstitial Lung Disease Center of Excellence and serves as associate dean of medical student research at Yale School of Medicine. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 30, 2022 Category: Universities & Medical Training Source Type: news